XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Xencor Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$23.19+0.34 (+1.49%)

Close on Oct 19, 2026

Market cap: $1.76B
P/E (TTM): –
Dividend yield: –

Xencor Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	126	110	175	165	275	123	157	41	46	109	–	–	–	–
Research & Development	239	228	254	200	193	170	119	98	72	52	34	19	17	13
General & Administrative	64	61	53	47	39	30	24	22	18	13	12	7.46	3.69	3.09
Operating Expenses	303	289	307	247	231	199	143	120	89	65	46	26	21	16
Operating Income	-178	-178	-132	-82	44	-77	14	-79	-43	44	-18	-16	-11	-6.23
Interest Expense	32	37	6.18	0.01	0.01	–	–	0.02	0.01	0.02	0.01	0.01	1.21	2.46
Interest & Investment Income	28	32	19	4.83	0.86	–	–	9.10	4.19	2.09	0.74	0.03	0.01	0.01
Income from Equity Investments	–	–	–	–	–	27	–	–	–	–	–	–	–	–
Other Non-Operating Income	88	-57	13	28	39	7.46	13	8.96	4.17	2.08	0.75	0.04	-50	-2.36
Asset Impairment Charges	9.17	20	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	102	-31	-0.40	23	39	0.11	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	-1.58	-1.38	-0.15	-0.46	0.00	-0.01	-0.10	-0.08	–	0.01	0.00	0.02	0.09
Legal Settlements	–	–	–	–	–	–	–	–	–	–	0.19	–	–	–
Pretax Income	-90	-235	-120	-55	83	-69	27	-70	-39	46	-18	-16	–	–
Income Tax Expense	2.50	1.62	14	0.67	0	0	0.31	0	-0.46	0.99	–	–	–	–
Net Income incl. Noncontrolling Interests	-92	-237	-133	-55	83	-69	27	-70	-38	45	-18	–	–	–
Minority Interest in Earnings	-0.21	-3.92	-0.16	0	0	–	–	–	–	–	–	–	–	–
Net Income	-92	-233	-133	-55	83	-69	27	-70	-38	45	-18	-16	-60	–
Net Income to Common	-92	-233	-133	-55	83	-69	27	-70	-38	45	-18	-16	85	-8.59
EPS (Basic)(per share)	-1.24	-3.58	-2.20	-0.93	1.42	-1.21	0.48	-1.31	-0.82	1.09	-0.45	-0.52	34.18	-118.86
EPS (Diluted)(per share)	-1.24	-3.58	-2.20	-0.93	1.37	-1.21	0.46	-1.31	-0.82	1.07	-0.45	-0.52	-3.85	-118.86
Shares Outstanding (Basic, Weighted)(shares)	74	65	61	60	58	57	57	54	47	41	39	31	2.47	0.07
Shares Outstanding (Diluted, Weighted)(shares)	74	65	61	60	60	57	58	54	47	42	39	31	16	0.07
EBITDA	-167	-166	-121	-74	51	-71	18	-76	-41	46	-17	-16	-9.81	-5.70
Net Interest Income	–	32	19	4.83	0.85	7.26	14	9.09	4.18	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -205.8%
Net margin: -155.6%
Return on equity, FY2025: -14.0%

Financial strength

Current ratio: 6.39
Debt to equity: 0.21
Debt to assets: 14.5%
Cash to current liabilities: 54.6%

Valuation

P/E ratio: –
Price to sales: 16.76
Price to book: 3.50
Dividend yield: –